Antiphospholipid syndrome induction exacerbates a transgenic Alzheimer disease model on a female background

Neurobiology of Aging

Volumn 32, Issue 2, 2011, Pages 272-279

  Katzav, Aviva ^a,b   Faust Socher, Achinoam ^a   Kvapil, Filip ^a   Michaelson, Daniel M ^b   Blank, Miri ^a   Pick, Chaim G ^b   Shoenfeld, Yehuda ^a   Korczyn, Amos D ^b   Chapman, Joab ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Activated microglia; Alzheimer's disease; Amyloid plaque; Amyloid precursor protein; Antiphospholipid syndrome; Behavior; Cognition; Transgenic mouse

Indexed keywords

ADJUVANT; AMYLOID PRECURSOR PROTEIN; BETA2 GLYCOPROTEIN 1;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BEHAVIOR CHANGE; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; GENE MUTATION; GENOTYPE; HISTOPATHOLOGY; MALE; MENTAL PERFORMANCE; MOTOR DYSFUNCTION; MOUSE; NERVE DEGENERATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN INTERACTION; SENILE PLAQUE; SWISS JAMES LAMBERT MOUSE; TRANSGENIC ANIMAL; WILD TYPE;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; DISEASE MODELS, ANIMAL; FEMALE; FREUND'S ADJUVANT; HUMANS; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROGLIA; MUTATION; PSYCHOMOTOR PERFORMANCE; SWIMMING;

EID: 78649887070     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2009.02.007     Document Type: Article

References (27)

1. Asherson R.A., Khamashta M.A., Gil A., Vazquez J.J., Chan O., Baguley E., Hughes G.R. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. Am. J. Med. 1989, 86:391-399.
2. Bakimer R., Fishman P., Blank M., Sredni B., Djaldetti M., Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J. Clin. Invest. 1992, 89:1558-1563.
3. Ball-Rosen C., Primak-Rubinovicz H., Korczyn A.D., Wang N., Farchi A., Shavit S., Shoenfeld Y., Chapman J. Identification of histidine-rich glycoprotein, a potential autoantigen, in human and rat brain preparations. Ann. N.Y. Acad. Sci. 2007, 1109:473-483.
4. Breteler M.M. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol. Aging 2000, 21:153-160.
5. Brey R.L., Chapman J., Levine S.R., Ruiz-Irastorza G., Derksen R.H., Khamashta M., Shoenfeld Y. Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. Lupus 2003, 12:508-513.
6. Caronti B., Pittoni V., Palladini G., Valesini G. Anti-beta 2-glycoprotein I antibodies bind to central nervous system. J. Neurol. Sci. 1998, 156:211-219.
7. Chapman J., Abu-Katash M., Inzelberg R., Yust I., Neufeld M.Y., Vardinon N., Treves T.A., Korczyn A.D. Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. J. Neurol. Sci. 2002, 203-204:81-84.
8. Chapman J., Cohen-Armon M., Shoenfeld Y., Korczyn A.D. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999, 8:127-133.
9. Chapman J., Rand J.H., Brey R.L., Levine S.R., Blatt I., Khamashta M.A., Shoenfeld Y. Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies. Lupus 2003, 12:514-517.
10. Chapman P.F., White G.L., Jones M.W., Cooper-Blacketer D., Marshall V.J., Irizarry M., Younkin L., Good M.A., Bliss T.V., Hyman B.T., Younkin S.G., Hsiao K.K. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 1999, 2:271-276.
11. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
12. Hsiao K.K., Borchelt D.R., Olson K., Johannsdottir R., Kitt C., Yunis W., Xu S., Eckman C., Younkin S., Price D., et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 1995, 15:1203-1218.
13. Katzav A., Litvinjuk Y., Pick C.G., Blank M., Shoenfeld Y., Sirota P., Chapman J. Genetic and immunological factors interact in a mouse model of CNS antiphospholipid syndrome. Behav. Brain Res. 2006, 169:289-293.
14. Katzav A., Pick C.G., Korczyn A.D., Oest E., Blank M., Shoenfeld Y., Chapman J. Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus 2001, 10:496-499.
15. King D.L., Arendash G.W. Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. Physiol. Behav. 2002, 75:627-642.
16. Mosek A., Yust I., Treves T.A., Vardinon N., Korczyn A.D., Chapman J. Dementia and antiphospholipid antibodies. Dement. Geriatr. Cogn. Disord. 2000, 11:36-38.
17. Polz E., Wurm H., Kostner G.M. Investigations on beta 2-glycoprotein-I in the rat: isolation from serum and demonstration in lipoprotein density fractions. Int. J. Biochem. 1980, 11:265-270.
18. Price D.L., Sisodia S.S., Borchelt D.R. Genetic neurodegenerative diseases: the human illness and transgenic models. Science 1998, 282:1079-1083.
19. Roubey R.A., Hoffman M. From antiphospholipid syndrome to antibody-mediated thrombosis. Lancet 1997, 350:1491-1493.
20. Ruiz-Irastorza G., Khamashta M.A., Hughes G.R. Hughes syndrome crosses boundaries. Autoimmun. Rev. 2002, 1:43-48.
21. Shrot S., Katzav A., Korczyn A.D., Litvinju Y., Hershenson R., Pick C.G., Blank M., Zaech J., Shoenfeld Y., Sirota P., Chapman J. Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. Lupus 2002, 11:736-743.
22. Snowdon D.A., Greiner L.H., Mortimer J.A., Riley K.P., Greiner P.A., Markesbery W.R. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997, 277:813-817.
23. Tanne D., Katzav A., Beilin O., Grigoriadis N.C., Blank M., Pick C.G., Landenberg P., Shoenfeld Y., Chapman J. Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome. Neurobiol. Dis. 2008, 30:56-64.
24. Tektonidou M.G., Varsou N., Kotoulas G., Antoniou A., Moutsopoulos H.M. Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch. Intern. Med. 2006, 166:2278-2284.
25. Verbeek M.M., Ruiter D.J., de Waal R.M. The role of amyloid in the pathogenesis of Alzheimer's disease. Biol. Chem. 1997, 378:937-950.
26. Westerman M.A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L.H., Carlson G.A., Younkin S.G., Ashe K.H. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 2002, 22:1858-1867.
27. Ziporen L., Polak-Charcon S., Korczyn D.A., Goldberg I., Afek A., Kopolovic J., Chapman J., Shoenfeld Y. Neurological dysfunction associated with antiphospholipid syndrome: histopathological brain findings of thrombotic changes in a mouse model. Clin. Dev. Immunol. 2004, 11:67-75.